Going Woke: An Insider's Look at Corporate America’s "Social Justice Scam"


By Dr. Richard D. Kocur


Coca-Cola, Google, Delta Airlines, Blackrock, Unilever, and Facebook. On its face, this list may sound like a great investment portfolio. Instead, as shown in a new book by former biotech CEO Vivek Ramaswamy, these companies serve as the posterchildren of woke capitalism.


Ramaswamy, author of Woke, Inc.- Inside Corporate America’s Social Justice Scam, uses examples from these companies, and many others, to assert his belief that woke organizations who signal commitments to various social causes do so to scam consumers with “the illusion that by engaging in normal acts of consumption we’re fulfilling our social obligations.” Said another way, consumers are being scammed to believe that supporting the right companies with our money somehow makes the world a better place.


Ramaswamy’s wide-ranging book clearly comes down in support of traditional shareholder capitalism—where the main duty of a company is the commitment to driving value for its shareholders. This is juxtaposed with many of the examples the author provides of stakeholder capitalism—defined by corporations that believe they have a duty to address the societal issues important to their stakeholders, such as climate change and racism. The obvious implication is that anyone could be a stakeholder and thus all issues facing society are issues worthy of corporate attention and support or opposition.


Even without the information presented in Woke, Inc., one can see stakeholder capitalism at play in the corporate actions following the death of George Floyd and the passage of Georgia’s voting law.


In one of the more interesting points in the book, the author links the increasingly woke actions of corporations with an ever-growing political divide; in essence, using companies as proxies to signal political identity. Ramaswamy states, “When corporations take sides in America’s partisan culture war, they’re not just signaling their tribe, they’re selling you an easy way to signal yours.”


The author’s point is exemplified by the tug-of-war over Goya Foods. When Goya Foods’ CEO Robert Unanue lauded President Donald Trump, Goya was immediately subject to boycotts and protests. If one purchased Goya products it signaled support for Trump, whereas conversely if one boycotted Goya, it was a statement in opposition to Trump. This trend is not just dangerous for companies like Goya, but for our democratic process in general. A preference for a particular soft drink, clothing brand, or chicken sandwich should have no bearing on political affiliation or social connections.


Ramaswamy also provides additional background on the rise of woke capitalism by noting the influence of big tech, academia, foreign governments, and what he calls the “new managerial class.” And though these areas are connected to the actions of many of today’s corporations, the author misses an opportunity to delve more deeply into the significant influence of social media, particularly Twitter, when it comes to corporate motivations. In addition, the reader of Woke, Inc. will likely be left wanting when it comes to solutions for stemming the influence of woke corporations. For example, the author’s proposal for protecting the speech rights of employees within a woke corporation are too legalistic and, frankly, unrealistic to consider viable. Lastly, while the actions of woke corporations are apparent and harmful, their true motivation for such actions are not entirely clear. Ramaswamy’s assertion that these corporations are purposefully using woke causes as an opportunity to increase profits at times borders on the conspiratorial.


Nonetheless, Woke, Inc. is an informative and enlightening book on the current state of corporate America and provides good background for those interested in learning more about stakeholder capitalism. Despite some of its shortcomings, it’s a book that can arm consumers with something more valuable than the buying power of any coupon. It provides them with the knowledge to make informed decisions about what, when, why, and from whom they buy.


Dr. Richard D. Kocur is an assistant professor of business at Grove City College. He specializes in marketing and business strategy and has over 25 years of experience in the healthcare industry.

More Resources


04/24/2024
Columbia Left-Wing Radicalism as Dangerous as It Was in 1968
More than 50 years after anti-Vietnam War demonstrators roiled the Columbia campus in 1968, anti-Israel agitators are disrupting the school's operations.

more info


04/24/2024
Abolish DEI Statements


more info


04/24/2024
Why Elites Are Rarely Held Accountable for Terrible Mistakes
Lionel Shriver on why elites are rarely held accountable for their most damaging mistakes.

more info


04/24/2024
MAGA 2.0
Can J.D. Vance keep it alive after Trump?

more info


04/24/2024
Will Israel Be a Game-Changer In The 2024 Election?
Republicans now the only major party that remains solid in its support for long-time ally Israel.

more info


04/24/2024
Iran vs. Israel: Outline of a Different Future Is Visible
Both seem keen to limit hostilities, and key Arab states are ready to resist Tehran. But real change will require new Israeli leadership, says Guardian columnist Jonathan Freedland

more info


04/24/2024
Taylor Swift: Why You Gotta Be So Mean?
In her latest album, the pop star crucifies ex-boyfriends like never before.

more info


04/24/2024
We're at Peak Sports Right Now for a Reason
Americans are tuning out a presidential election in favor of distractions.

more info


04/24/2024
Young People Are Enraged, Opting Out of America
NYU business school professor Scott Galloway talks to MSNBC's "Morning Joe" about why young people are struggling economically:

more info


04/24/2024
In 2024, Americans Will Be Voting Like It's 1892
Both candidates have a record, and we know which president saw success and which one has only produced one crisis after another.

more info


04/24/2024
On Trial, Trump Isn't the Superhero MAGA Craves
He wants his devotees to see the court case as trial by combat, with him as warrior. But the truth is more pathetic

more info


04/24/2024
Trump's Trial Will Only Help Him
If Trump should be reelected in November, he may owe his victory in no small part to Alvin Bragg and Juan Merchan.

more info


04/24/2024
Student Protesters Are Schooling Their Universities
What is a university for? At Columbia University and its affiliated women's college, Barnard, it is ostensibly to value critical thought, a broad mind, and a commitment to reason.

more info


04/24/2024
Meet the Zoomerwaffen
The Jewish Question: It's (Suddenly) Complicated. Plus: A big personal reveal!

more info


04/24/2024
'Grading for Equity' Is Hurting School Kids
Joe Feldman has faced many tough crowds in the course of successfully selling his "Grading for Equity" program to school districts across the nation. During the consultant's presentations, teachers concerned that his approach lowers standards have rolled their eyes, questioned his understanding of students, and worse.

more info



Custom Search

More Politics Articles:

Related Articles

Americans Can't Afford Insurance — and Obamacare is to Blame


The number of uninsured Americans rose in 2018 for the first time since the Affordable Care Act passed in 2010, according to the Census Bureau.

ICER Discriminates Against People with Rare Diseases


FDA officials approved a record number of rare disease treatments last year. One groundbreaking medicine treats an inherited bone condition that causes intense pain and immobility. Another treats Fabry disease, a genetic condition that can lead to kidney failure or stroke.

Minor Legislation with Massive Implications


U.S. Senator Ron Johnson (R-WI) is promoting the "Prevent Government Shutdown Act of 2019." The goal of the act is to prevent disruptive government shutdowns.

When Humans Don't Procreate


The "hook" of the story intrigued me: "This hasn't happened in all of modern history..." An email from "The Crux" last month blared, "Global population growth to virtually stop by 2100."

Beware of Bills in Sheep's Clothing


There is a bipartisan tradition of naming bills such that no reasonable person would oppose them. For instance, changes to our tax system came with the passage of the Tax Cuts and Jobs Act. Who's against jobs? And how could anyone have voted against the Patient Protection and Affordable Care Act (i.e., "Obamacare")?

Offshore Bans Hurt Working Class Americans


Congressional Democrats just betrayed America's working class.

If You Like Your Health Plan, You Can't Keep It Under a Public Option


Nearly two in three Americans support the creation of a government-sponsored health plan to compete against plans offered by private insurers, according to the most recent survey data from the Kaiser Family Foundation.

Don't Legalize Discrimination Against People With Disabilities


Imagine if the federal government treated disabled Americans as second-class citizens. It's an appalling thought. But it could happen soon -- if some special interest groups get their way.

It's Time to Turn the Prescription Drug Debate on its Head


Politicians typically blame drug companies for soaring pharmacy prices. But insurers, pharmacies, and other middlemen are the real driving force behind rising drug spending.

U.S. Carbon Emissions Are Actually Dropping


Increased natural gas consumption helped bring down U.S. greenhouse gas emissions in 2019, according to a recent report from the U.S. Energy Information Administration.

"Buy American" Executive Order Could Slow Delivery of a Coronavirus Cure


President Trump is considering a "Buy American" executive order requiring government agencies to purchase medicines and medical supplies domestically.

Don't Disrupt the Supply Chain in the Midst of a Pandemic


The Trump administration fears America has lost its ability to mass-produce the medicines and medical supplies needed to fight the coronavirus and other, future pandemics. So it's considering an executive order to bring drug and medical-supply manufacturing back to the United States.

Intellectual Property Makes Sure Drug Makers Deliver


House Democrats Peter DeFazio, Rosa DeLauro, Lloyd Doggett, and Jan Schakowsky want to nullify intellectual property rights on any experimental treatments for COVID-19. They believe their proposals will prevent "price gouging and profiteering" without harming innovation.

Move These Projects Forward and Get America Back to Work


With more than 40 million Americans out of a job due to the coronavirus pandemic, states are scrambling to help the unemployed and laying plans to reopen the economy.

COVID-19 Cost-Effectiveness Research Deepens Racial Disparities


A newly released study by the Institute for Clinical and Economic Review (ICER), a Boston-based nonprofit, attempts to answer a weighty question: How much should it cost to treat the coronavirus?